Ipilimumab reacts with CTLA-4 on melanoma cell lines and tissues and is able to trigger antibody dependent cellular cytotoxicity (ADCC) engaging FcγRIIIA on lymphocyte subsets such as primary NK cells, IL-2 activated NK and γδT cells. This evidence concerns the gene IL2 and melanoma.